Why the study?
What are the anesthetic considerations and implications for a patient with myofibrillar myopathy (BAG3-myopathy)?
What are the anesthetic considerations and implications for a patient with myofibrillar myopathy (BAG3-myopathy)?
This first report of anesthetic management in myofibrillar myopathy highlights critical considerations for preventing malignant hyperthermia and rhabdomyolysis in affected patients.
May guide MH precautions in BAG3-myopathy; leaves open generalizability pending larger studies.
Myofibrillar myopathy (MFM) is a relatively newly recognized genetic disease that leads to progressive muscle deterioration. MFM has a varied phenotypic presentation and impacts cardiac, skeletal, and smooth muscles. Affected individuals are at increased risk of respiratory failure, significant cardiac conduction abnormalities, cardiomyopathy, and sudden cardiac death. In addition, significant skeletal muscle involvement is common, which may lead to contractures, respiratory insufficiency, and airway compromise as the disease progresses. This study is the first report of anesthetic management of a patient with MFM. We report multiple anesthetic encounters of a child with genetically confirmed BAG3-myopathy, a subtype of MFM with severe childhood disease onset. A review of the anesthetic implications of the disease is provided, with specific exploration of possible susceptibility to malignant hyperthermia, rhabdomyolysis, and sensitivity to other anesthetic agents.
No takes yet. Share an insight, caveat, or question.
Latham et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: